Literature DB >> 33255417

TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia.

Sergiu Pasca1,2, Ancuta Jurj3, Ciprian Tomuleasa1,2,4, Mihnea Zdrenghea1,4.   

Abstract

Background and objectives: Mutational analysis has led to a better understanding of acute myeloid leukemia (AML) biology and to an improvement in clinical management. Some of the most important mutations that affect AML biology are represented by mutations in genes related to methylation, more specifically: TET2, IDH1, IDH2 and WT1. Because it has been shown in numerous studies that mutations in these genes lead to similar expression profiles and phenotypes in AML, we decided to assess if mutations in any of those genes interact with other genes important for AML. Materials and
Methods: We downloaded the clinical data, mutational profile and expression profile from the TCGA LAML dataset via cBioPortal. Data were analyzed using classical statistical methods and functional enrichment analysis software represented by STRING and GOrilla.
Results: The first step we took was to assess the 196 AML cases that had a mutational profile available and observe the mutations that overlapped with TET2/IDH1/2/WT1 mutations. We observed that RUNX1 mutations significantly overlap with TET2/IDH1/2/WT1 mutations. Because of this, we decided to further investigate the role of RUNX1 mutations in modulating the level of RUNX1 mRNA and observed that RUNX1 mutant cases presented higher levels of RUNX1 mRNA. Because there were only 16 cases of RUNX1 mutant samples and that mutations in this gene determined a change in mRNA expression, we further observed the correlation between RUNX1 and other mRNAs in subgroups regarding the presence of hypermethylating mutations and NPM1. Here, we observed that both TET2/IDH1/2/WT1 and NPM1 mutations increase the number of genes negatively correlated with RUNX1 and that these genes were significantly linked to myeloid activation. Conclusions: In the current study, we have shown that NPM1 and TET2/IDH1/2/WT1 mutations increase the number of negative correlations of RUNX1 with other transcripts involved in myeloid differentiation.

Entities:  

Keywords:  NPM1; RUNX1; TET2; acute myeloid leukemia

Mesh:

Substances:

Year:  2020        PMID: 33255417      PMCID: PMC7760270          DOI: 10.3390/medicina56120637

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  38 in total

1.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Authors:  Kelly Moran-Crusio; Linsey Reavie; Alan Shih; Omar Abdel-Wahab; Delphine Ndiaye-Lobry; Camille Lobry; Maria E Figueroa; Aparna Vasanthakumar; Jay Patel; Xinyang Zhao; Fabiana Perna; Suveg Pandey; Jozef Madzo; Chunxiao Song; Qing Dai; Chuan He; Sherif Ibrahim; Miloslav Beran; Jiri Zavadil; Stephen D Nimer; Ari Melnick; Lucy A Godley; Iannis Aifantis; Ross L Levine
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

2.  RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells.

Authors:  Takahiro Suzuki; Yuri Shimizu; Erina Furuhata; Shiori Maeda; Mami Kishima; Hajime Nishimura; Saaya Enomoto; Yoshihide Hayashizaki; Harukazu Suzuki
Journal:  Blood Adv       Date:  2017-09-06

Review 3.  TET2 in Normal and Malignant Hematopoiesis.

Authors:  Robert L Bowman; Ross L Levine
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

Review 4.  Acute myeloid leukaemia.

Authors:  Asim Khwaja; Magnus Bjorkholm; Rosemary E Gale; Ross L Levine; Craig T Jordan; Gerhard Ehninger; Clara D Bloomfield; Eli Estey; Alan Burnett; Jan J Cornelissen; David A Scheinberg; Didier Bouscary; David C Linch
Journal:  Nat Rev Dis Primers       Date:  2016-03-10       Impact factor: 52.329

5.  WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.

Authors:  Yiping Wang; Mengtao Xiao; Xiufei Chen; Leilei Chen; Yanping Xu; Lei Lv; Pu Wang; Hui Yang; Shenghong Ma; Huaipeng Lin; Bo Jiao; Ruibao Ren; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Mol Cell       Date:  2015-01-15       Impact factor: 17.970

6.  Identification of a critical regulatory site in the human interleukin-3 promoter by in vivo footprinting.

Authors:  S Cameron; D S Taylor; E C TePas; N A Speck; B Mathey-Prevot
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

7.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

Review 8.  Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?

Authors:  Craig W Freyer; Neha Gupta; Meir Wetzler; Eunice S Wang
Journal:  Am J Hematol       Date:  2014-10-25       Impact factor: 10.047

9.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

10.  NANOG-dependent function of TET1 and TET2 in establishment of pluripotency.

Authors:  Yael Costa; Junjun Ding; Thorold W Theunissen; Francesco Faiola; Timothy A Hore; Pavel V Shliaha; Miguel Fidalgo; Arven Saunders; Moyra Lawrence; Sabine Dietmann; Satyabrata Das; Dana N Levasseur; Zhe Li; Mingjiang Xu; Wolf Reik; José C R Silva; Jianlong Wang
Journal:  Nature       Date:  2013-02-10       Impact factor: 49.962

View more
  1 in total

Review 1.  The Potential Equivalents of TET2 Mutations.

Authors:  Sergiu Pasca; Ancuta Jurj; Mihnea Zdrenghea; Ciprian Tomuleasa
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.